pembrolizumab

You have access
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy
MINEHIKO INOMATA, SHUHEI MINATOYAMA, NAOKI TAKATA, KANA HAYASHI, TAKAHIRO HIRAI, ZENTA SETO, KOTARO TOKUI, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI, TOSHIRO MIWA, KEI MATSUYAMA, RYUJI HAYASHI, SHOKO MATSUI and KAZUYUKI TOBE

Anticancer Research March 2024, 44 (3) 1241-1245; DOI: https://doi.org/10.21873/anticanres.16920
You have access
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
TETSUYA SHINDO, KOHEI HASHIMOTO, ATSUSHI TAKAHASHI, SHINTARO MIYAMOTO, YASUHARU KUNISHIMA, SHUNSUKE SATO, FUMIMASA FUKUTA, YOSHIKI HIYAMA, AKIO TAKAYANAGI, RYUICHI KATO, ATSUSHI WANIFUCHI, YOHEI UEKI, MANABU OKADA, HIDEKI ADACHI, KO KOBAYASHI, TOSHIAKI TANAKA and NAOYA MASUMORI; on behalf of the Sapporo Medical University Urologic Oncology Consortium

Anticancer Research March 2024, 44 (3) 1271-1279; DOI: https://doi.org/10.21873/anticanres.16922
You have access
Advanced Renal Cell Carcinoma With Inferior Vena Cava Thrombus Treated With a Combination of Preoperative Lenvatinib and Pembrolizumab
CHIKA NAGAHISA, KAZUHIKO YOSHIDA, HANAE KONDO, TAKAYUKI NAKAYAMA, SHINSUKE MIZOGUCHI, RYO MINODA, HIRONORI FUKUDA, YUKI KOBARI, JUNPEI IIZUKA, YOJI NAGASHIMA, HIDEKI ISHIDA and TOSHIO TAKAGI

Anticancer Research March 2024, 44 (3) 1317-1321; DOI: https://doi.org/10.21873/anticanres.16927
You have access
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site
NAOTAKA NISHIYAMA, YUKI KITA, KATSUHIRO ITO, MINORU KATO, SHINGO HATAKEYAMA, YUTO MATSUSHITA, SEI NAITO, MAKITO MIYAKE, SHOTARO NAKANISHI, YOICHIRO KATO, TADAMASA SHIBUYA, TETSUTARO HAYASHI, HIROAKI YASUMOTO, TAKASHI YOSHIDA, MOTOHIDE UEMURA, RIKIYA TAOKA, HIROYUKI NISHIYAMA, TAKASHI KOBAYASHI and HIROSHI KITAMURA; on behalf of the Japan Urological Oncology Group

Anticancer Research November 2023, 43 (11) 5041-5050; DOI: https://doi.org/10.21873/anticanres.16703
You have access
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TAKAHITO NEGISHI, NAOTAKA SAKAMOTO, YOOHYUN SONG, YOSHIFUMI HORI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, MIRII HARADA, SHINGO TAMURA, HIROKI KOBAYASHI, KAEDE MORIHARA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA

Anticancer Research October 2023, 43 (10) 4701-4708; DOI: https://doi.org/10.21873/anticanres.16666
You have access
Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GAI YAMASHITA, ISAKU OKAMOTO, TATSUYA ITO, KUNIHIKO TOKASHIKI, TAKURO OKADA and KIYOAKI TSUKAHARA

Anticancer Research August 2023, 43 (8) 3679-3683; DOI: https://doi.org/10.21873/anticanres.16550
You have access
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, KUNIHIKO TOKASHIKI, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, TATSUO MASUBUCHI, YUICHIRO TADA, KOKI MIURA, GO OMURA, TAKU YAMASHITA, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA

Anticancer Research June 2023, 43 (6) 2717-2724; DOI: https://doi.org/10.21873/anticanres.16438
You have access
Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature
LUKAS CHINCZEWSKI, FELIX WILHELM FELDHAUS, WOLFGANG SCHMITT, IOANA BRAICU, EVA ROSER and JALID SEHOULI

Anticancer Research April 2023, 43 (4) 1655-1662; DOI: https://doi.org/10.21873/anticanres.16317
Open Access
Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE

Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
Open Access
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
SANDRO M. WAGNER, TERESA MAGNES, THOMAS MELCHARDT, DOMINIK KIEM, LUKAS WEISS, DANIEL NEUREITER, CHRISTINA WAGNER, MARIE-BERNADETTE ARETIN, STEFAN NEMEC, GABRIELE GAMERITH, GEORG PALL, RICHARD GREIL and THORSTEN FUEREDER

Anticancer Research March 2023, 43 (3) 1273-1282; DOI: https://doi.org/10.21873/anticanres.16274

Main menu

User menu

Search

pembrolizumab

Pages